Reversing cellular sits at the center of this dementia and brain health question.
Recent research suggests that reversing cellular age could be genuinely key to preventing—and even treating—Alzheimer’s disease. A landmark study published in Cell Reports Medicine in December 2025 demonstrated that restoring NAD+, a central molecule in cellular energy production, not only prevented Alzheimer’s pathology in animal models but completely reversed it, restoring normal cognitive function even in advanced disease stages. This finding fundamentally shifts how scientists think about Alzheimer’s: rather than viewing it as an inevitable consequence of aging, it suggests that cellular aging itself is the root mechanism—and that aging, at the cellular level, can be interrupted. For example, when researchers used a drug candidate called P7C3-A20 to restore NAD+ balance in the brains of mice with Alzheimer’s, the neurological damage reversed completely, with memory and cognitive function returning to normal. This article explores what this discovery means, which other cellular aging mechanisms are being targeted, what tools can identify dementia risk years in advance, and which interventions are being studied—while being clear about what remains animal research and what may soon be tested in humans.
The implications are substantial if the findings translate from mice to humans. NAD+ is a naturally occurring molecule that declines steadily with age in all organisms. By the time Alzheimer’s symptoms appear clinically, NAD+ levels in the brain have often fallen significantly. The research suggests that this depletion is not incidental to Alzheimer’s—it is central to how the disease develops. Restoring NAD+ without pushing it to abnormal levels appears to reset the cellular damage, creating a path toward treatment rather than mere symptom management. However, all current reversal findings come from animal models; clinical trials in humans are still in development.
Table of Contents
- How Does Cellular Age Relate to Alzheimer’s Disease?
- What Are Epigenetic Clocks and Why Do They Matter for Dementia Prevention?
- What Is the Tau Protein, and How Can It Be Stopped?
- What Are the Practical Interventions Being Studied Right Now?
- What Are the Major Limitations and Unknowns Still Remaining?
- How Do Modifiable Risk Factors Fit Into This Picture?
- Neuroinflammation and the “Dark Microglia” Breakthrough
- Conclusion
- Frequently Asked Questions
How Does Cellular Age Relate to Alzheimer’s Disease?
Cellular aging—the gradual accumulation of damage and dysfunction at the molecular level—appears to be the fundamental driver of Alzheimer’s disease, not merely a risk factor. When cells age, they lose their ability to maintain critical molecules like NAD+, which is essential for energy production, DNA repair, and maintaining healthy mitochondria. As NAD+ drops, cells become less able to clear out toxic proteins, repair damage, and communicate properly. This cellular dysfunction then leads to the hallmark pathology of Alzheimer’s: accumulation of amyloid-beta and tau proteins, inflammation, and ultimately neuronal death. The connection between cellular age and Alzheimer’s age is so strong that researchers now use “epigenetic clocks”—mathematical models that read the aging pattern written into your DNA—and these clocks can predict who will develop dementia up to three years before any symptoms appear, often more accurately than chronological age alone. The importance of this shift cannot be overstated. If Alzheimer’s is fundamentally a disease of accelerated cellular aging, then treating it means reversing aging, not just clearing plaques or reducing inflammation.
This is why the NAD+ breakthrough matters so much: it shows that the cellular damage can be undone. In the Cell Reports Medicine study, researchers didn’t just slow down cognitive decline—they reversed it completely. Mice that had already developed Alzheimer’s pathology and memory loss regained normal cognitive function when NAD+ balance was restored. This suggests that the disease is not irreversible once it starts, at least in animal models. However, there is an important limitation: NAD+ restoration only works if it targets the right molecular pathways. Simply increasing NAD+ to high levels does not work and may even be harmful. The drug candidate P7C3-A20 is designed specifically to help cells maintain proper NAD+ balance without elevating it to abnormal levels. This precision matters—a blunt increase in NAD+ is not the same as restoring NAD+ balance, and the distinction will be crucial as treatments move toward human trials.
What Are Epigenetic Clocks and Why Do They Matter for Dementia Prevention?
Epigenetic clocks are tools that read the “aging clock” written into human DNA through a process called DNA methylation—chemical tags on genes that accumulate with age and are associated with aging and disease. Remarkably, this epigenetic age can diverge significantly from chronological age. Some people in their 70s have epigenetic ages closer to 50; others in their 50s have cells that look biologically much older. This divergence—called epigenetic age acceleration—is associated with increased risk of diseases including Alzheimer’s. The critical finding is that epigenetic clocks can predict who will develop dementia up to three years before any clinical symptoms appear, and they often predict disease onset more accurately than simply knowing someone’s age. This predictive power opens a window for intervention. If someone’s epigenetic clock shows age acceleration, it signals that cellular aging is progressing faster than it should—a warning sign for future cognitive decline.
This is fundamentally different from waiting for memory problems to appear. For example, a 60-year-old person might have an epigenetic age of 75, indicating accelerated cellular aging; epigenetic clocks could flag this person as high-risk for dementia in the next few years, allowing for preventive interventions to begin before symptoms develop. Recent research shows that epigenetic age acceleration is reversible through interventions including NAD+ and sirtuin boosters, HDAC inhibitors, and certain lifestyle changes. The implication is that dementia prevention might be possible for those who can be identified early. However, epigenetic clocks remain research tools, not yet widely available in clinical practice. Interpretation requires understanding that correlation is not perfect—some people with age acceleration never develop dementia, and some develop it without showing acceleration. Additionally, reversing epigenetic age acceleration in humans has been shown in small studies and animal models, but we lack large-scale evidence that reversing epigenetic age actually prevents dementia in people. The promise is there, but the clinical translation is still underway.
What Is the Tau Protein, and How Can It Be Stopped?
Tau is one of the two hallmark proteins in Alzheimer’s disease, along with amyloid-beta. Tau normally helps stabilize structures inside neurons, but in Alzheimer’s, it becomes misfolded, tangles up, and accumulates, ultimately killing the neurons it inhabits. For decades, researchers have tried to prevent tau accumulation, with limited success. A recent breakthrough revealed that an enzyme called OTULIN acts as a key trigger for tau buildup in the brain. OTULIN regulates the immune system and, when overactive, promotes tau accumulation. When researchers disabled OTULIN in their studies, tau completely vanished from neurons, and brain cells remained healthy. This discovery offers a potential new point of intervention: instead of trying to clear tau after it accumulates, you could prevent it from accumulating in the first place by controlling OTULIN activity. The significance of targeting OTULIN is that it addresses tau at the source rather than as a downstream consequence.
Most anti-tau therapies have focused on clearing existing tangles or blocking tau aggregation after it has already formed. Controlling OTULIN is earlier in the cascade—it addresses why tau accumulates in the first place. This approach is conceptually similar to how doctors might stop a flood by closing a dam rather than mopping the floor. In animal models, the approach works: disabling OTULIN stopped tau accumulation and prevented the neurodegeneration that usually follows. Yet this research is still in early stages. OTULIN is an immune regulatory enzyme, and simply blocking it could have off-target effects elsewhere in the body or brain. Additionally, human brains are far more complex than mouse brains, and immune-related interventions sometimes behave differently in people than they do in rodents. Clinical trials would need to carefully test whether OTULIN inhibitors can safely prevent or treat tau pathology in humans without causing unexpected side effects. For now, OTULIN represents a promising research direction, not a treatment available outside of clinical trials.
What Are the Practical Interventions Being Studied Right Now?
Several specific interventions are currently being researched to reverse or prevent cellular aging and dementia. One is AKG (alpha-ketoglutarate), a naturally occurring molecule that declines with age and appears to improve communication between brain cells and restore early memory abilities in animal studies. Another is lithium orotate, a compound containing lithium, a naturally occurring element already present in the brain. A Harvard study found that lithium orotate prevented and reversed Alzheimer’s pathology and memory loss in mouse models. P7C3-A20, the NAD+-restoring drug mentioned earlier, is perhaps the most advanced: it has completed animal studies and human trials are in development. Additionally, sirtuin activators and HDAC inhibitors—classes of drugs that help preserve NAD+ and reverse epigenetic age acceleration—are being investigated. The diversity of these approaches reflects the reality that cellular aging happens through multiple mechanisms, and targeting one (NAD+ or epigenetic age) may not capture all of them.
A practical advantage of some of these candidates is that they are small molecules or natural compounds that can be administered as pills, unlike antibody-based therapies that require infusions. Another advantage is that lithium, AKG, and NAD+ precursors already exist in nature, reducing some safety concerns. However, the doses used in human trials will likely be much higher than what people would naturally ingest, and animal studies always overestimate what will work in humans—many compounds showing promise in mice have failed in human trials. The timeline matters. P7C3-A20 is progressing toward human trials, meaning it could potentially be available within the next several years if it proves safe and effective. AKG and lithium orotate supplements exist commercially, but commercial availability does not mean they have been tested for dementia prevention in humans. Some people with bipolar disorder take lithium clinically, but lithium orotate (an over-the-counter form) has not been systematically studied for Alzheimer’s prevention in rigorous trials. NAD+ precursors like NMN and NR are sold as supplements, but again, there is no definitive evidence that taking them prevents or treats dementia in humans, though they do increase cellular NAD+ levels in short-term studies.
What Are the Major Limitations and Unknowns Still Remaining?
The most critical limitation is that all the reversal findings—complete recovery from Alzheimer’s pathology and memory loss—come from animal models, specifically mice. Mouse brains are vastly simpler than human brains, with different lifespans, immune systems, metabolism, and protein dynamics. Translation to humans may be straightforward, or it may fail entirely. Historical precedent is not encouraging: dozens of Alzheimer’s drugs have worked perfectly in mice and failed in humans. Additionally, the mice in these studies had Alzheimer’s induced artificially (genetic models) or triggered by injection; naturally aged mice with spontaneous Alzheimer’s sometimes respond differently. Some of the interventions tested (like directly disabling OTULIN) also cannot be tested the same way in humans for safety reasons. Another limitation is that we do not yet understand whether reversing cellular age in healthy tissue actually reverses Alzheimer’s, or whether there is a point of no return.
Once tau and amyloid-beta accumulate to extreme levels and neurons die, can restoration of NAD+ bring those neurons back? Probably not. The mouse studies showed reversal in models of early to mid-stage disease, but it is unclear what the window of reversibility is in humans. Additionally, mouse studies typically treat the disease as if it is a pure brain problem, but human Alzheimer’s is influenced by systemic factors—cardiovascular health, gut microbiome, metabolic syndrome, and genetics—that are harder to model. There is also the practical question of access and side effects. If NAD+-restoring drugs prove effective, they will likely be expensive when they first reach the market, and development timelines have historically been long. HDAC inhibitors, for example, have known side effects when used systemically. Targeting immune molecules like OTULIN carries risks of off-target effects. These drugs will not be simple supplements; they will require careful dosing, monitoring, and clinical supervision.
How Do Modifiable Risk Factors Fit Into This Picture?
While cellular aging mechanisms are important, it is critical to recognize that 45 percent of overall dementia risk is attributable to modifiable factors—conditions and behaviors that people can change. These include midlife hypertension, low social engagement, untreated hearing loss, high cholesterol, and air pollution exposure. This statistic is profound: it means that nearly half of dementia cases could theoretically be prevented through lifestyle and medical interventions, without waiting for a new drug. Someone with well-controlled blood pressure, an active social life, good hearing correction, healthy cholesterol, and low air pollution exposure has substantially lower dementia risk, regardless of their epigenetic age or NAD+ levels. The question is how these modifiable factors relate to the cellular aging mechanisms being discussed. Hypertension damages blood vessels, reducing blood flow to the brain and accelerating cellular aging.
Social isolation is associated with systemic inflammation and accelerated epigenetic aging. Hearing loss forces the brain to work harder to process sound, increasing metabolic stress. Air pollution delivers particles and inflammatory molecules directly into the bloodstream and brain. In other words, these modifiable risk factors likely exert their effects partly through the same cellular aging pathways—NAD+ depletion, epigenetic acceleration, neuroinflammation—that researchers are now trying to reverse with drugs. This suggests that optimizing modifiable factors now and then adding NAD+-restoring or epigenetic-reversing drugs later could be a two-pronged approach to dementia prevention. The practical implication is that waiting for a new drug is not a sensible strategy if you can modify your risk now. Blood pressure management, hearing correction, cognitive engagement, social connection, and air quality improvements are not glamorous compared to novel pharmaceuticals, but they are proven and available today.
Neuroinflammation and the “Dark Microglia” Breakthrough
A related discovery involves microglia, the immune cells of the brain. Researchers have identified a particularly harmful subset called “dark microglia,” which accumulates under stress and neurodegeneration. Strikingly, dark microglia are present at twice the levels in Alzheimer’s patients compared to healthy aging individuals. When researchers inhibited the cellular stress response (ISR) that activates dark microglia in mouse models, they prevented both synapse loss and tau accumulation—the hallmark pathology of Alzheimer’s. This suggests that neuroinflammation, driven by activated microglia, is a central mechanism linking cellular stress to tau pathology.
Dark microglia appear to be both a cause and a consequence of cellular aging. When cells age and NAD+ declines, cellular stress increases, microglia become activated, and they release inflammatory molecules that further damage neurons. This creates a feedback loop. Breaking that loop—either by restoring NAD+ and reducing cellular stress, or by directly inhibiting microglia activation—might slow or reverse this cascade. Some of the HDAC inhibitors being studied may work partly through reducing microglia activation. This is another example of how multiple pathways in aging contribute to dementia, and why multi-targeted interventions may ultimately be necessary.
Conclusion
Recent discoveries in cellular aging biology have fundamentally reframed Alzheimer’s disease: it is not an inevitable consequence of getting older, but rather a disease driven by specific, reversible mechanisms of cellular aging, including NAD+ depletion, epigenetic age acceleration, tau accumulation, and neuroinflammation. In animal models, reversing these mechanisms has reversed Alzheimer’s pathology and restored cognitive function completely. Epigenetic clocks can now identify people at high risk for dementia three years before symptoms appear, creating a window for early intervention.
Drug candidates like P7C3-A20 and compounds like AKG and lithium orotate are in human trials or development, and researchers have identified specific molecular targets like OTULIN and dark microglia that offer new angles of attack. However, all reversal findings are currently from animal models, and translation to humans will require careful clinical trials over multiple years. In the meantime, the evidence strongly supports addressing the 45 percent of dementia risk that is modifiable through lifestyle and medical management—controlling blood pressure, maintaining social engagement, correcting hearing loss, managing cholesterol, and reducing air pollution exposure. Combining proven risk factor modification today with emerging cellular aging therapies as they become available may offer the most effective path toward meaningful dementia prevention.
Frequently Asked Questions
If my epigenetic age shows I am aging faster, does that mean I will definitely get Alzheimer’s?
No. Epigenetic age acceleration increases risk, but it is not deterministic. Some people with accelerated epigenetic aging never develop dementia, and some people with normal epigenetic aging do. Epigenetic clocks are a risk signal, not a diagnosis or certainty. If your epigenetic age indicates acceleration, it is a reason to discuss with your doctor and potentially increase preventive efforts, but not a guarantee of future disease.
Can I take NAD+ supplements right now to prevent Alzheimer’s?
NAD+ precursors like NMN and NR are available as supplements and do increase cellular NAD+ in short-term studies. However, they have not been tested in large-scale human trials for Alzheimer’s prevention. The drug candidate P7C3-A20 is specifically designed to restore NAD+ balance without elevating it abnormally, and this precision may matter; simply taking more NAD+ is not the same thing. If you are interested in NAD+ boosting, discuss it with your doctor, but understand that it is not yet proven to prevent dementia in humans.
Does lithium orotate work for Alzheimer’s prevention?
Lithium orotate prevented and reversed Alzheimer’s in mouse models in a Harvard study, but it has not been tested in human trials for this purpose. Lithium carbonate (prescription lithium) is used for bipolar disorder, but it has different pharmacokinetics and side effects than lithium orotate supplements. Over-the-counter lithium orotate is not regulated as a drug, and no large-scale human studies have confirmed it prevents or treats Alzheimer’s.
How long before these treatments are available to the general public?
P7C3-A20 is the most advanced and may enter human trials within the next 1-2 years if development proceeds on schedule. If it proves safe and effective, it could potentially reach patients through early-access programs or FDA approval within 5-10 years, depending on trial results. Other approaches like HDAC inhibitors are further back in development. This timeline is typical for drug development and could accelerate or extend depending on trial outcomes.
What should I do right now if I am worried about dementia risk?
Focus on modifiable risk factors, which account for 45 percent of dementia risk: manage blood pressure, stay socially and cognitively engaged, correct hearing loss, maintain healthy cholesterol, and reduce air pollution exposure. If you have a family history of Alzheimer’s, discuss it with your doctor and ask about whether epigenetic testing or other risk assessments might be appropriate for you. Stay informed about clinical trials, as some may be recruiting participants in your area.
Are these animal study results too good to be true?
The results are striking—complete reversal of Alzheimer’s pathology and memory loss in mice. However, animal studies frequently overestimate efficacy in humans. Dozens of drugs that worked perfectly in mouse models have failed in humans. Translation to humans will require careful clinical trials. The promise is genuine, but caution and rigorous testing are essential before claiming that these approaches will work the same way in people.
You Might Also Like
- University Lab Develops Promising Alzheimer’s Treatment Approach
- Texas Researchers Develop New Approaches to Prevent Alzheimer’s
- Senior Living Facility Faces Lawsuit Over Alzheimer’s Patient Assault
For more, see NIH MedlinePlus — dementia.
